Company profile for Prevail Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Prevail Therapeutics, we are developing a pipeline of gene therapies to slow or stop the underlying disease process for patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases. Our programs utilize a precision medicine approach targeting patient populations with urgent ...
At Prevail Therapeutics, we are developing a pipeline of gene therapies to slow or stop the underlying disease process for patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
430 East 29th Street, Suite 940 New York, NY 10016
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250428937434/en/Scribe-Achieves-Milestone-for-In-Vivo-Program-in-Collaboration-with-Prevail-Therapeutics-a-part-of-Lillys-Gene-Therapy-Division-and-Announces-ASGCT-Joint-Presentation-on-Self-Inactivating-AAV-Technology-for-Neurological-and-Neuromuscular-Disorders

BUSINESSWIRE
28 Apr 2025

https://www.accesswire.com/923249/prevail-partners-and-prevail-infoworks-enter-into-strategic-investment-and-clinical-alliance-with-kairos-pharma-ltd

ACCESSWIRE
25 Sep 2024
Lilly's Prevail walks away from Precision gene editing collab
Lilly's Prevail walks away from Precision gene editing collab

17 Apr 2024

// James Waldron FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/lillys-prevail-walks-away-gene-editing-collab-precision

James Waldron FIERCE BIOTECH
17 Apr 2024

https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-research-evaluation-and-option

PRESS RELEASE
18 Jul 2023
Lilly's Prevail drops deal value for Precision gene therapy pact
Lilly's Prevail drops deal value for Precision gene therapy pact

07 Jul 2023

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/lillys-prevail-revises-26b-biobucks-deal-precision-taking-more-preclinical-responsibilities

Gabrielle Masson FIERCE BIOTECH
07 Jul 2023
Scribe's CRISPR tech Prevails with new $1.5B Lilly biobucks deal
Scribe's CRISPR tech Prevails with new $1.5B Lilly biobucks deal

17 May 2023

// Gabrielle Masson FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/lillys-prevail-inks-15b-pact-doudnas-scribe-crispr-tech

Gabrielle Masson FIERCE BIOTECH
17 May 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty